News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Illumina, Inc. (ILMN) Announces Pricing Of Convertible Senior Notes


6/6/2014 8:33:39 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) today announced the pricing of an offering of $550 million aggregate principal amount of its 0% convertible senior notes due 2019 (the "2019 Notes") and $450 million aggregate principal amount of its 0.5% convertible senior notes due 2021 (the "2021 Notes" and, together with the 2019 Notes, the “Notes”). The Notes are being offered to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Illumina has granted the initial purchasers an option to purchase up to an additional $82.5 million aggregate principal amount of the 2019 Notes and $67.5 million aggregate principal amount of the 2021 Notes on the same terms and conditions referenced above. The 2019 Notes will not bear interest and will mature on June 15, 2019, unless earlier repurchased or converted. Interest on the 2021 Notes will be paid semi-annually at a rate of 0.50% per year and the Notes will mature on June 15, 2021, unless earlier repurchased or converted.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES